

Paris, July 2<sup>nd</sup>, 2015

## Quantum Genomics speeds its development work in the field of heart failure

- 🌀 **Signs a research collaboration agreement with University of Ottawa Heart Institute and the Center for Interdisciplinary Research in Biology at College de France**
- 🌀 **Announces goal to launch a Phase IIa human clinical trial by mid-2016**

**Quantum Genomics (Alternext - FR0011648971 - ALQGC)**, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces its intention to speed its research and development work on its QGC101 drug candidate for the prevention and treatment of heart failure. The promising results obtained in trials in dogs by a major company in the field of animal health ([see the press release of June 29, 2015](#)), support Quantum Genomics' ambitions in this indication.

With this in mind, Quantum Genomics announces the signing of a research collaboration agreement with the team led by Prof Frans Leenen at the University of Ottawa Heart Institute and the team led by Dr Catherine Llorens-Cortès at the Center for Interdisciplinary Research in Biology (Inserm U1050/CNRS UMR 7241) at College de France.

The purpose of this research collaboration agreement is to evaluate, in rats having undergone myocardial infarction, the effect of repeated administrations of the product for 28 days, on heart function, sympathetic tone, concentrations of hormonal biomarkers of heart failure, and the animals' survival rate.

Quantum Genomics intends to use this research collaboration to further demonstrate the therapeutic potential of brain aminopeptidase A inhibitors (BAPAs) in the prevention and treatment of heart failure.

In parallel, Quantum Genomics intends to launch a Phase IIa clinical trial in humans for QGC101 by mid-2016.

### More than 23 million people worldwide affected by heart failure

Heart failure is a major public health problem with a persistent urgent need for new therapeutic treatments. Despite some medical advances, the vital prognosis associated with heart failure is very poor as more than 50% of people diagnosed with heart failure die within five years.

Heart failure today affects some 5.7 million people in the United States alone, according to American Heart Association data (Source: *Circulation* 2015, Vol. 131 (4): e29-e322), and more than 23 million worldwide. Direct and indirect annual costs connected with heart failure worldwide in 2012 were an estimated 108 billion dollars (Source: *Int. J. Cardiol.* 2014, vol. 171 (3):368-76).

## CONTACTS

### **Quantum Genomics**

Lionel Ségard  
Chairman & Chief Executive Officer  
+33 1 85 34 77 77

### **Quantum Genomics**

Marc Karako  
CFO – Investor Relations  
+33 1 85 34 77 75  
[marc.karako@quantum-genomics.com](mailto:marc.karako@quantum-genomics.com)

### **ACTUS finance & communication**

Jean-Michel Marmillon  
Press Relations  
+33 1 53 67 36 73  
[jmarmillon@actus.fr](mailto:jmarmillon@actus.fr)

## ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, Inserm, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).